|Bid||261.81 x 800|
|Ask||261.87 x 800|
|Day's Range||260.41 - 262.26|
|52 Week Range||191.53 - 263.37|
|PE Ratio (TTM)||107.33|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||3.00 (1.15%)|
|1y Target Est||268.07|
Thermo Fisher Scientific (TMO) operates in four business segments. The Analytical Instruments segment provides instruments, software, and services for use in laboratory applications. The segment’s revenue rose from $1.17 billion in the second quarter of 2017 to $1.31 billion in the second quarter of 2018 due to increased demand for chromatography and mass spectrometry and electron microscopy. This increase came from the strong performance of the healthcare market channel and clinical diagnostic products.
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017.
Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company will acquire Becton Dickinson’s (BDX) advanced bioprocessing business.
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.
Thermo Fisher Scientific (TMO) provides equipment, software, analytical instruments, reagents, consumables, and services. Thermo Fisher reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion, a 21.8% increase as compared to ~$5.0 billion during the second quarter of 2017. The below chart compares revenues and EPS for Thermo Fisher Scientific since the first quarter of 2017.
Fortunately, Simply Safe Dividends identified the 10 best dividend growth stocks that investors can rely on for secure, fast-growing income. Let’s take a look at 10 of the safest dividend stocks in the market.
From January 2–28, 2018, Teleflex (TFX) stock rose from $254.73 to $287.65, which was its high point so far in 2018. During the broader market turmoil in February, it dipped to a low of $242.67 on March 1. Then it made a steady recovery to $280 in June but has corrected again to its current level of $248.
Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018. Its income taxes, on the other hand, decreased from $12.1 million in the second quarter of 2017 to $9.58 million in the second quarter of 2018.
Teleflex’s (TFX) geographic segments include the United States, Europe, Asia, and other. Teleflex incurred a total cost of sales of $265.09 million in the second quarter of 2018 compared to $238.3 million in the second quarter of 2017. For fiscal 2018, Teleflex’s gross margins are expected to be 57.56% compared to 55.76% for fiscal 2017.
"The sale of our Advanced Bioprocessing business will create greater focus for our Life Sciences segment where BD has outstanding opportunities to contribute significant innovation for disease and therapy research and clinical diagnostics," said Patrick Kaltenbach, president of Life Sciences for BD.
WALTHAM, Mass. , Sept. 6, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement with BD (Becton, Dickinson and Company – ...
(Corrects paragraph 9 spelling to McCann instead of McGann) By Mark Miller CHICAGO, Sept 5 (Reuters) - Dale Kleber is an experienced attorney, but when he spotted an ad back in 2014 for a corporate law position at a medical device and services company that specified “no more than seven years of experience,” he applied anyway. At age 58, Kleber had extensive experience working for law firms, as an in-house general counsel and in general management jobs. Kleber’s search for senior-level general counsel positions had proved fruitless, so he widened his scope to include more junior positions.
Becton Dickinson’s (BDX) Life Sciences segment, reported revenues of $1.1 billion in the fiscal third quarter of 2018 compared to $997 million in the fiscal third quarter of 2017, reflecting an ~8.2% YoY growth.
In the fiscal third quarter, Becton Dickinson’s (BDX) Medication Management Solutions segment reported revenues of $610 million compared to $556 million in the fiscal third quarter of 2017, reflecting a ~9% YoY growth.
Becton Dickinson (BDX) generated revenues of $4.3 billion in the fiscal third quarter compared to $1.5 billion in the fiscal third quarter of 2017, reflecting a ~41% YoY (year-over-year) growth. The acquisition of C.R. Bard primarily contributed to Becton Dickinson’s revenue growth in the third quarter.
On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65. It hit its 52-week high of $259.99 and was a ~35% growth from its 52-week low of $191.53 on September 21, 2017.